Jay H. Hoofnagle

63.1k total citations · 22 hit papers
393 papers, 43.8k citations indexed

About

Jay H. Hoofnagle is a scholar working on Epidemiology, Hepatology and Pharmacology. According to data from OpenAlex, Jay H. Hoofnagle has authored 393 papers receiving a total of 43.8k indexed citations (citations by other indexed papers that have themselves been cited), including 289 papers in Epidemiology, 270 papers in Hepatology and 62 papers in Pharmacology. Recurrent topics in Jay H. Hoofnagle's work include Hepatitis B Virus Studies (204 papers), Hepatitis C virus research (199 papers) and Liver Disease Diagnosis and Treatment (195 papers). Jay H. Hoofnagle is often cited by papers focused on Hepatitis B Virus Studies (204 papers), Hepatitis C virus research (199 papers) and Liver Disease Diagnosis and Treatment (195 papers). Jay H. Hoofnagle collaborates with scholars based in United States, Canada and United Kingdom. Jay H. Hoofnagle's co-authors include Adrian M. Di Bisceglie, Leonard B. Seeff, David E. Kleiner, Jules L. Dienstag, Jordan J. Feld, Girish N. Vyas, Jeanne G. Waggoner, T. Jake Liang, Yoon Park and Michael A. Gerber and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Jay H. Hoofnagle

389 papers receiving 41.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

2010 2.5k citations Arun J. Sanyal, Naga Chalasani et al. profile →
Classification of chronic hepatitis: Diagnosis, grading and staging

1994 2.2k citations Jay H. Hoofnagle et al. Hepatology profile →
Viral Hepatitis and Liver Disease

1985 1.6k citations Jay H. Hoofnagle et al. profile →
Recombinant Interferon Alfa Therapy for Chronic Hepatitis C

1989 1.1k citations Adrian M. Di Bisceglie, Jeanne G. Waggoner et al. profile →
Course and outcome of hepatitis C

2002 837 citations Jay H. Hoofnagle Hepatology profile →
The Treatment of Chronic Viral Hepatitis

1997 779 citations Jay H. Hoofnagle, Adrian M. Di Bisceglie profile →
Mechanism of action of interferon and ribavirin in treatment of hepatitis C

2005 758 citations Jordan J. Feld, Jay H. Hoofnagle profile →
Treatment of Chronic Non-A, Non-B Hepatitis with Recombinant Human Alpha Interferon

1986 740 citations Jay H. Hoofnagle, Adrian M. Di Bisceglie et al. profile →
Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C

2000 718 citations T. Jake Liang, Jay H. Hoofnagle et al. Annals of Internal Medicine profile →
Management of hepatitis B: 2000—Summary of a workshop

2001 610 citations Jay H. Hoofnagle et al. Gastroenterology profile →
Hepatitis C: The clinical spectrum of disease

1997 609 citations Jay H. Hoofnagle Hepatology profile →
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis† ‡

2004 587 citations Glen Lutchman, Alejandro Soza et al. Hepatology profile →
Impaired Effector Function of Hepatitis C Virus-Specific CD8+ T Cells in Chronic Hepatitis C Virus Infection

2002 535 citations Jay H. Hoofnagle et al. profile →
Acute liver failure

2008 520 citations Edward Doo, Jay H. Hoofnagle et al. Hepatology profile →
Seroconversion from Hepatitis B e Antigen to Antibody in Chronic Type B Hepatitis

1981 519 citations Jay H. Hoofnagle et al. Annals of Internal Medicine profile →
Routes of Infection, Viremia, and Liver Disease in Blood Donors Found to Have Hepatitis C Virus Infection

1996 510 citations Jay H. Hoofnagle et al. profile →
Drug-Induced Liver Injury — Types and Phenotypes

2019 417 citations Jay H. Hoofnagle, Einar S. Björnsson profile →
Ratio of Serum Aspartate to Alanine Aminotransferase in Chronic Hepatitis Relationship to Cirrhosis

1988 387 citations Jay H. Hoofnagle et al. Gastroenterology profile →
Hepatitis E

2012 364 citations Jay H. Hoofnagle et al. profile →
Type B Hepatitis after Transfusion with Blood Containing Antibody to Hepatitis B Core Antigen

1978 352 citations Jay H. Hoofnagle et al. profile →
Liver injury from herbal and dietary supplements

2016 286 citations Victor J. Navarro, Einar S. Björnsson et al. Hepatology profile →
Biliary Atresia: Clinical and Research Challenges for the Twenty‐First Century

2018 218 citations Jay H. Hoofnagle, Edward Doo et al. Hepatology profile →

Peers

Countries citing papers authored by Jay H. Hoofnagle

Since Specialization

Citations

This map shows the geographic impact of Jay H. Hoofnagle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jay H. Hoofnagle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jay H. Hoofnagle more than expected).

Fields of papers citing papers by Jay H. Hoofnagle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jay H. Hoofnagle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jay H. Hoofnagle. The network helps show where Jay H. Hoofnagle may publish in the future.

Co-authorship network of co-authors of Jay H. Hoofnagle

This figure shows the co-authorship network connecting the top 25 collaborators of Jay H. Hoofnagle. A scholar is included among the top collaborators of Jay H. Hoofnagle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jay H. Hoofnagle. Jay H. Hoofnagle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Genetic and non-genetic drivers of histological progression and regression in MASLD 2025 ·Journal of Hepatology ·Eduardo Vilar‐Gómez, Katherine P. Yates, David E. Kleiner, Cynthia Behling, Oscar W. Cummings, Laura Wilson, Tiebing Liang, (unknown), Rohit S. Loomba, Jeffrey B. Schwimmer, Arun J. Sanyal, Jay H. Hoofnagle, Naga Chalasani	1
2	Refinement of Hy Law Using the Drug-Induced Liver Injury Network Database 2024 ·The American Journal of Gastroenterology ·(unknown), Paul H. Hayashi, Andrew Stolz, Huiman X. Barnhart, Jay H. Hoofnagle, (unknown)	3
3	Clinical features, outcomes, and HLA risk factors associated with nitrofurantoin-induced liver injury 2022 ·Journal of Hepatology ·Naga Chalasani, Yi‐Ju Li, Andrew Dellinger, Victor J. Navarro, Herbert L. Bonkovsky, Robert J. Fontana, Jiezhun Gu, Huiman X. Barnhart, Elizabeth Phillips, Craig Lammert, Tae‐Hwi Schwantes‐An, Paola Nicoletti, David E. Kleiner, Jay H. Hoofnagle	25
4	A revised electronic version of RUCAM for the diagnosis of DILI 2022 ·Repositorio Institucional de la Universidad de Málaga (University of Málaga) ·Paul H. Hayashi, M. Isabel Lucena, Robert J. Fontana, Einar S. Björnsson, Guruprasad P. Aithal, Huiman X. Barnhart, A. González-Jiménez, Qinghong Yang, Jiezhun Gu, Raúl J. Andrade, Jay H. Hoofnagle	74
5	Michael Charles Kew: A chronicle of his career 2018 ·South African Medical Journal ·Jay H. Hoofnagle	1
6	Liver injury from nonsteroidal anti‐inflammatory drugs in the United States 2015 ·Liver International ·Paul A. Schmeltzer, Andrzej S. Kosinski, David E. Kleiner, Jay H. Hoofnagle, Andrew Stolz, Robert J. Fontana, Mark W. Russo, (unknown)	67
7	Long-term therapy of chronic delta hepatitis with peginterferon alfa 2014 ·Alimentary Pharmacology & Therapeutics ·Theo Heller, Yaron Rotman, Christopher Koh, Shauna Clark, Vanessa Haynes–Williams, Richard Chang, Robert P. McBurney, Peter Schmid, J. Albrecht, David E. Kleiner, Marc G. Ghany, T. Jake Liang, Jay H. Hoofnagle	81
8	Introducing the AASLD President: Adrian Di Bisceglie 2013 ·Hepatology ·Jay H. Hoofnagle	1
9	Low‐ and standard‐dose peginterferon alfa‐2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response 2010 ·Alimentary Pharmacology & Therapeutics ·Yaron Rotman, Brian B. Borg, Alejandro Soza, Jordan J. Feld, Apurva A. Modi, Rohit Loomba, Glen Lutchman, Elenita Rivera, Edward Doo, Marc G. Ghany, Theo Heller, Avidan U. Neumann, T. Jake Liang, Jay H. Hoofnagle	7
10	Action Plan for Liver Disease Research 2004 ·Hepatology ·Jay H. Hoofnagle	22
11	Hepatitis C : biomedical research reports 2000 ·Academic Press eBooks ·T. Jake Liang, Jay H. Hoofnagle	18
12	Liver transplantation for alcoholic liver disease: Executive statement and recommendations 1997 ·Liver Transplantation and Surgery ·Jay H. Hoofnagle, Thomas F. Kresina, Richard K. Fuller, John R. Lake, Michael R. Lucey, M. F. Sorrell, Thomas P. Beresford	47
13	Dose-finding study of interferon alfa-n3 in hepatitis 1997 ·Hepatology ·Jay H. Hoofnagle	4
14	Predictors of a sustained beneficial response to interferon alfa therapy in chronic hepatitis C 1995 ·Hepatology ·Hari S. Conjeevaram, James E. Everhart, Jay H. Hoofnagle	34
15	Ribavirin as Therapy for Chronic Hepatitis C 1995 ·Annals of Internal Medicine ·Adrian M. Di Bisceglie, Hari S. Conjeevaram, Michael Fried, Richard Sallie, Yoon Park, Cihan Yurdaydın, Mark G. Swain, David E. Kleiner, (unknown), Jay H. Hoofnagle	72
16	Thymosin treatment of chronic hepatitis B: A placebo-controlled pilot trial 1991 ·Hepatology ·Milton G. Mutchnick, Henry D. Appelman, Hau-Tim Chung, Emma Aragona, (unknown), G. D. Cummings, Jeanne G. Waggoner, Jay H. Hoofnagle, David A. Shafritz	114
17	Hepatitis B virus deoxyribonucleic acid in liver of chronic carriers 1987 ·Gastroenterology ·Adrian M. Di Bisceglie, Jeanne G. Waggoner, Jay H. Hoofnagle	14
18	Effects of Recombinant Human Leukocyte Interferon Treatment on Endogenous Interferon Production in Patients with Chronic Type-B Hepatitis 1986 ·Journal of Interferon Research ·Douglas L. Jicha, Gary L. Davis, Marion G. Peters, Jay H. Hoofnagle, E. Anthony Jones	8
19	Lipoprotein abnormalities in primary biliary cirrhosis 1985 ·Gastroenterology ·C. Jahn, Ernst J. Schaefer, L Taam, Jay H. Hoofnagle, Frank T. Lindgren, John J. Albers, E. Anthony Jones, H Bryan Brewer	41
20	Immune response in fulminant viral hepatitis, type B. 1976 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·Edward Tabor, Robert J. Gerety, Jay H. Hoofnagle, Lewellys F. Barker	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact